March 12, 2024 10:30 AM EDT
Bioregnum
R&D
Special

The R&D 15: Top phar­ma play­ers shell out record $153B for re­search, and M&A is a prime fo­cus for all

John Carroll

Editor & Founder

At a time when biotech is still count­ing its loss­es as a thaw grad­u­al­ly sets in af­ter the long mar­ket win­ter, phar­ma has been on …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times